NEW YORK (GenomeWeb News) – Pacific Biosciences saw its second-quarter revenues fall 31 percent year over year, the company reported after the close of the market on Thursday, but the firm beat consensus Wall Street estimates on the top line and the bottom line.

For the three months ended June 30, PacBio took in $7.3 million in revenues, down from $10.6 million a year ago. Revenues beat analysts projections, however, which averaged $6.9 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.